Collects spinal fluid and blood samples from people with Huntington's disease
Collects spinal fluid and blood samples from people with Huntington's disease at different stages.
Plain-language title generated from the registry record
Registry title: HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
Key facts
- Where
- Bochum, Dresden, Erlangen, Münster, Taufkirchen, and Ulm, GermanySee the 6 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people at different stages of Huntington's disease, and also control volunteers, to give a spinal fluid (CSF) sample and a blood plasma sample for research.
- Age
- 18-75 years for controls, early or late premanifest HD and incomplete penetrance HD; 21-75 years for early, moderate or advanced manifest HD; 11 years or older for juvenile HD.
- Sex
- All sexes can join.
- Disease stage
- People at different stages of Huntington's disease (HD), from premanifest to advanced; controls can also join.
- Earlier treatment
- No drug trial within 30 days, and no antiplatelet or anticoagulant therapy within 14 days, before a sampling visit.
- Biomarker or test result
- Everyone except family and community controls must have had a genetic test for HD.
Main reasons for not taking part
- Drug trial within 30 days of any sampling visit
- Changes in medication used to treat HD within 30 days
- Antiplatelet or anticoagulant therapy within 14 days
- Clotting or bruising disorder, needle phobia, headache, or spinal surgery or deformity
- Positive urine pregnancy test for women who could become pregnant
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 11 and 75 years old?
Source: NCT02855476, who can take part
Where in Germany
- St Josef And Elisabeth HospitalBochum, GermanyContact: Barbara KaminskiTaking people
- Dresden UniversityDresden, GermanyContact: Stefan BräuerTaking people
- University Hospital of ErlangenErlangen, GermanyContact: Susanne SeifertTaking people
- George Huntington InstituteMünster, GermanyContact: Svenja AufenbergTaking people
- kbo-Isar-Amper-Klinikum Taufkirchen (Vils)Taufkirchen, GermanyContact: Michael BachmaierTaking people
- University Hospital UlmUlm, GermanyContact: Olga KuvarzinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University College, London
- Trial code
- NCT02855476
- Record updated
- 27 April 2026
- Original description
HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.Read full original descriptionShow less
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.
Inclusion: Age (18-75 years controls, early/late premanifest HD and incomplete penetrance HD, 21-75 years early/moderate/advanced manifest HD, ≥11 years juvenile HD); Enroll HD participant; Capable of consenting or have a legal representative (parent/guardian for juveniles); Capable of complying with study procedures; All participants other than family and community controls must have had a genetic test for HD.
Exclusion: Drug trial within 30 days of any sampling visit; Changes in medication (antidepressant, psychoactive, psychotropic or other medications or nutraceuticals used to treat HD within 30 days); Antiplatelet or anticoagulant therapy within 14 days; Needle phobia, headache, spinal surgery / deformity; Drug / alcohol abuse; Serious adverse event related to HDClarity study procedures or any lumbar puncture procedure performed for any reason in the previous 30 days; Clotting or bruising disorder; Significant comorbidity; Screening blood test abnormalities >10% outside normal range; Positive urine pregnancy test at any screening or sampling visit for females of childbearing potential; Predictable non compliance or unwillingness.